The use of interleukin-2 in human immunodeficiency virus infection.
Advances in antiretroviral therapy for human immunodeficiency virus (HIV) have led to reductions in HIV-related morbidity and mortality. Although antiretroviral therapy has shown success in suppressing viral loads, it does not adequately restore the immune system in all individuals infected with HIV. In light of this incomplete success, interleukin (IL)-2 is being evaluated as adjunctive therapy to antiretroviral therapy. The agent has demonstrated mixed yet promising results in restoring immune function in patients who are HIV positive.
Anaya
Jaime P
JP
University of Texas at El Paso-University of Texas at Austin Cooperative Pharmacy Program, El Paso, Texas 79902, USA.
Sias
Jeri J
JJ
D017326:Clinical Trials, Phase III as Topic; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007376:Interleukin-2 / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D007376:Interleukin-2